Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD.

Autor:	Kennedy, Nicholas A., Simeng Lin, Goodhand, James R., Chanchlani, Neil, Hamilton, Benjamin, Bewshea, Claire, Nice, Rachel, Chee, Desmond, Cummings, J. R. Fraser, Fraser, Aileen, Irving, Peter M., Kamperidis, Nikolaos, Kok, Klaartje B., Lamb, Christopher Andrew, Macdonald, Jonathan, Mehta, Shameer, Pollok, Richard C. G., Raine, Tim, Smith, Philip J., Verma, Ajay Mark
Předmět:	MEDICAL personnel COVID-19 vaccines SARS-CoV-2 INFLIXIMAB MEDICAL research INTESTINAL diseases
Zdroj:	Gut; Oct2021, Vol. 70 Issue 10, p1884-1893, 10p
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu